GeneLink, Inc. Stock

Equities

GNLKQ

US36870F1075

Healthcare Facilities & Services

Market Closed - OTC Markets 14:48:16 2024-01-29 EST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for GeneLink, Inc. -.--% -.--%
Sales 2011 4.68M 6.43M Sales 2012 2.14M 2.93M Capitalization 2.56M 3.51M
Net income 2011 -3M -4.12M Net income 2012 -3M -4.12M EV / Sales 2011 2.72 x
Net Debt 2011 429K 588K Net Debt 2012 931K 1.28M EV / Sales 2012 1.63 x
P/E ratio 2011
-2.89 x
P/E ratio 2012
-0.71 x
Employees -
Yield 2011 *
-
Yield 2012
-
Free-Float 98.38%
More Fundamentals * Assessed data
Dynamic Chart
3 years
0.00
Extreme 1.0E-6
0.00
5 years
0.00
Extreme 1.0E-6
0.01
10 years
0.00
Extreme 1.0E-6
0.01
More quotes
Managers TitleAgeSince
Founder 77 94-09-20
Chief Executive Officer 77 98-12-31
Director of Finance/CFO 56 12-08-31
Members of the board TitleAgeSince
Chief Executive Officer 77 98-12-31
Founder 77 94-09-20
More insiders
Genelink, Inc. is a supplier of custom oligonucleotides. The Company offers a range of commercially available modifications, fluorescently labeled probes, and specialized probes, such as Molecular Beacons, TaqMan, and Fluorescence resonance energy transfer (FRET), as well as a variety of other molecular biology products, such as linkers, adaptors, deoxyribonucleic acid (DNA) purification and clean-up kits. The Company’s product line of gene detection systems comprises reagents and reagent systems for scientists in the detection of genetic disorders. The Company focuses on triple repeat disorders, which include fragile x, myotonic dystrophy, huntington's disease. It also specializes in the synthesis of ribonucleic acid (RNA) modified oligos, RNA fluorescent probes with quenchers, chimeric oligos containing various combinations of DNA, 2'O methyl bases and phosphorothioate linkages. It serves various industries, including research institutes, pharmaceutical companies and hospitals.
More about the company